RU2019120162A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019120162A3 RU2019120162A3 RU2019120162A RU2019120162A RU2019120162A3 RU 2019120162 A3 RU2019120162 A3 RU 2019120162A3 RU 2019120162 A RU2019120162 A RU 2019120162A RU 2019120162 A RU2019120162 A RU 2019120162A RU 2019120162 A3 RU2019120162 A3 RU 2019120162A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016905126A AU2016905126A0 (en) | 2016-12-12 | Non-peptide oxytocin receptor agonists | |
| AU2016905126 | 2016-12-12 | ||
| PCT/AU2017/051371 WO2018107216A1 (en) | 2016-12-12 | 2017-12-12 | Non-peptide oxytocin receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019120162A RU2019120162A (ru) | 2021-01-12 |
| RU2019120162A3 true RU2019120162A3 (https=) | 2021-01-28 |
Family
ID=62557695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019120162A RU2019120162A (ru) | 2016-12-12 | 2017-12-12 | Непептидные агонисты рецепторов окситоцина |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11491165B2 (https=) |
| EP (2) | EP4494705A3 (https=) |
| JP (3) | JP7089649B2 (https=) |
| KR (1) | KR102561721B1 (https=) |
| CN (1) | CN110248944A (https=) |
| AU (1) | AU2017377653B2 (https=) |
| BR (1) | BR112019012049A2 (https=) |
| CA (1) | CA3046809A1 (https=) |
| DK (1) | DK3551631T3 (https=) |
| ES (1) | ES3001195T3 (https=) |
| FI (1) | FI3551631T3 (https=) |
| HU (1) | HUE070078T2 (https=) |
| IL (1) | IL267276B2 (https=) |
| MX (1) | MX2019006942A (https=) |
| PL (1) | PL3551631T3 (https=) |
| PT (1) | PT3551631T (https=) |
| RU (1) | RU2019120162A (https=) |
| SI (1) | SI3551631T1 (https=) |
| WO (1) | WO2018107216A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220079953A1 (en) * | 2018-11-23 | 2022-03-17 | The University Of Sydney | Methods for management of weight |
| KR20220063198A (ko) * | 2019-09-06 | 2022-05-17 | 키녹시스 테라퓨틱스 피티와이 리미티드 | 아편유사제 금단의 치료 |
| JP2022548581A (ja) | 2019-09-13 | 2022-11-21 | オリゲニス ゲーエムベーハー | 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物 |
| JP2023552485A (ja) * | 2020-12-14 | 2023-12-15 | キノシス・セラピューティクス・ピーティーワイ・リミテッド | オキシトシン受容体モジュレーター |
| AU2022240104A1 (en) * | 2021-03-18 | 2023-10-05 | Kinoxis Therapeutics Pty Ltd | Methods of treatment |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3770762A (en) * | 1972-08-29 | 1973-11-06 | Parke Davis & Co | Diazepine compounds and methods for their production |
| AR002459A1 (es) | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
| US5536718A (en) * | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB0115515D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Oxytocin agonisys |
| GB0120051D0 (en) * | 2001-08-16 | 2001-10-10 | Ferring Bv | Oxytocin agonists |
| EP1449844A1 (en) * | 2003-02-14 | 2004-08-25 | Ferring B.V. | benzamide derivatives as oxytocin agonists and vasopressin antagonists |
| US7342112B2 (en) * | 2003-07-01 | 2008-03-11 | Ppg Industries Ohio, Inc. | Photochromic compounds |
| EP1512687A1 (en) * | 2003-09-05 | 2005-03-09 | Ferring B.V. | Piperazines as oxytocin agonists |
| EP1632494A1 (en) * | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| KR100858262B1 (ko) * | 2004-10-13 | 2008-09-11 | 에프. 호프만-라 로슈 아게 | Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀 |
| CN101203516A (zh) * | 2005-04-05 | 2008-06-18 | 法马科皮亚公司 | 用于免疫抑制的嘌呤及咪唑并吡啶衍生物 |
| AU2006306547A1 (en) | 2005-10-24 | 2007-05-03 | Wyeth | Tricyclic compounds useful as oxytocin receptor agonists |
| WO2008103382A1 (en) * | 2007-02-20 | 2008-08-28 | Sergey Kozmin | Method for assembling high-purity chemical libraries, compounds suppressing acetyl coenzyme a carboxylase activities discovered by same |
| GB0903493D0 (en) * | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| US10508108B2 (en) * | 2014-12-05 | 2019-12-17 | Merck Sharp & Dohme Corp. | Tricyclic compounds as inhibitors of mutant IDH enzymes |
| PL3328864T3 (pl) * | 2015-07-06 | 2023-02-27 | Kinoxis Therapeutics Pty Ltd | Związki i kompozycje terapeutyczne do leczenia zaburzeń społecznych i zaburzeń związanych z używaniem substancji psychoaktywnych |
-
2017
- 2017-12-12 CA CA3046809A patent/CA3046809A1/en active Pending
- 2017-12-12 ES ES17880082T patent/ES3001195T3/es active Active
- 2017-12-12 PL PL17880082.7T patent/PL3551631T3/pl unknown
- 2017-12-12 KR KR1020197019977A patent/KR102561721B1/ko active Active
- 2017-12-12 IL IL267276A patent/IL267276B2/en unknown
- 2017-12-12 AU AU2017377653A patent/AU2017377653B2/en active Active
- 2017-12-12 PT PT178800827T patent/PT3551631T/pt unknown
- 2017-12-12 FI FIEP17880082.7T patent/FI3551631T3/fi active
- 2017-12-12 RU RU2019120162A patent/RU2019120162A/ru unknown
- 2017-12-12 CN CN201780085825.XA patent/CN110248944A/zh active Pending
- 2017-12-12 BR BR112019012049-1A patent/BR112019012049A2/pt active Search and Examination
- 2017-12-12 HU HUE17880082A patent/HUE070078T2/hu unknown
- 2017-12-12 JP JP2019531447A patent/JP7089649B2/ja active Active
- 2017-12-12 WO PCT/AU2017/051371 patent/WO2018107216A1/en not_active Ceased
- 2017-12-12 EP EP24212001.2A patent/EP4494705A3/en active Pending
- 2017-12-12 SI SI201731588T patent/SI3551631T1/sl unknown
- 2017-12-12 MX MX2019006942A patent/MX2019006942A/es unknown
- 2017-12-12 EP EP17880082.7A patent/EP3551631B9/en active Active
- 2017-12-12 DK DK17880082.7T patent/DK3551631T3/da active
-
2019
- 2019-06-12 US US16/439,570 patent/US11491165B2/en active Active
-
2022
- 2022-05-11 JP JP2022078250A patent/JP2022097655A/ja active Pending
- 2022-09-16 US US17/932,914 patent/US20230330103A1/en active Pending
-
2024
- 2024-06-05 JP JP2024091625A patent/JP2024107136A/ja active Pending
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |